Table 1.

Baseline characteristics

Characteristic	Pharm-TCR (n = 20)	TAU (n = 16)	P-value
Sex
Male (%)	40.0	37.5
Female (%)	60.0	62.5
Body mass (kg)	98.2 ± 18.0	102.7 ± 17.4	0.46
Body mass index (kg/m2)	32.4 [30.6–37.6]	32.6 [31.1–37.6]	0.97
Age (years)	58.5 ± 8.3	58.1 ± 12.2	0.90
HbA1c (%)	7.4 ± 0.9	7.9 ± 1.1	0.17
Fasting glucose (mmol/L)	7.9 [6.4–9.3]	8.6 [7.1–10.1]	0.78
Fasting Insulin (pmol/L)	63.4 [30.9-103.5]	110.0 [46.8-124.1]	0.48
Fasting C-peptide (pmol/L)	770.4 ± 412.8	1003.7 ± 446.5	0.12
Fasting proinsulin (pmol/L)	9.5 [6.2–17.9]	7.6 [6.0-16.1]	0.54
Proinsulin to C-peptide ratio	0.01 [0.009–0.02]	0.01 [0.005–0.02]	0.78
Insulin to C-peptide ratio	0.1 [0.06–0.1]	0.09 [0.07–0.1]	0.93
HOMA2 IR	1.3 [0.7–2.3]	2.1 [1.1–2.6]	0.60
HOMA2 B (%)	56.3 ± 28.2	72.4 ± 46.4	0.52
miR375 (starting quantity)	162.2 [116.9-185.9]	129.0 [96.3-193.5]	1.00
Hepatic steatosis index	46.7 [43.3–53.5]	46.4 [44.5–53.5]	0.77
Fatty liver index	84.1 [72.0-95.2]	92.4 [85.5–95.3]	0.26
Fetuin-A (ng/mL)	145.8 [124.1-169.3]	163.9 [137.0-180.5]	0.39
FGF21 (pg/mL)	304.2 [200.8-550.8]	577.0 [478.6-787.5]	0.01
T2D duration (yrs)	11.0 [2.8–16.2]	6.0 [4.0–10.0]	0.60
Medication effect score	1.4 [0.7–2.5]	1.2 [0.7-2.0]	0.24
Diabetes Medications (n %)
DPP4 Inhibitors	6 (30%)	0 (0%)
GLP1 Agonists	3 (15%)	4 (25%)
Insulin	3 (15%)	3 (19%)
Metformin	19 (95%)	13 (81%)
SGLT2 Inhibitors	5 (25%)	1 (6%)
Sulfonylureas	8 (40%)	2 (12%)
Thiazolidinediones	1 (5%)	0 (0%)

Data are mean ± standard deviation or median [25th to 75th percentile]. HbA1c Hemoglobin A1c, HOMA2 IR Homeostatic model assessment insulin resistance, HOMA2 B Homeostatic model assessment beta-cell function, miR375 Micro RNA 375, FGF21 Fibroblast growth factor 21, GGT Gamma-glutamyl transferase, AST Aspartate transaminase, ALT Alanine transaminase, DPP4 Dipeptidyl peptidase-4, GLP1 Glucagon-like peptide-1, SGLT2 Sodium-glucose transport protein 2